Combating COVID-19 with mesenchymal stem cell therapy

Rajarshi, Keshav; Chatterjee, Aroni; Ray, Shashwati

doi:10.1016/j.btre.2020.e00467

Cited by 84 publications

(90 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results confirmed the therapeutic potential of MSCs to treat patients with COVID-19 ( Fig. 4E and F) [105].…”

Section: Msc Therapy In Viral Infections: Preclinical and Clinical Apsupporting

confidence: 78%

“…The pathogenesis of SARS-CoV-2 has been identified by the interaction and binding of the virus spike glycoprotein (SARS-CoV-2S) to the angiotensin-converting enzyme-related carboxypeptidase (ACE2) on the target cell surface, followed by activation of spike protein by the cellular transmembrane protease serine 2 (TMPRSS2) and virus enters the host cell [101,[105][106][107].…”

Section: Msc Therapy In Viral Infections: Preclinical and Clinical Apmentioning

confidence: 99%

“…Nowadays, the COVID-19 pandemic represents a public health emergency and has prompted an urgent need for novel or alternative therapies [5,103,105,[123][124][125][126][127]. Almost every patient with COVID-19 presents with lung involvement, whereas severe complications, such as ARDS, are only observed in a subgroup of severe patients.…”

Section: Future Directions Of Msc-based Therapies For Covid-19 and Otmentioning

confidence: 99%

See 2 more Smart Citations

Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19

Rocha

Oliveira

Noronha

et al. 2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) constitute a heterogeneous population of stromal cells with immunomodulatory and regenerative properties that support their therapeutic use. MSCs isolated from many tissue sources replicate vigorously in vitro and maintain their main biological properties allowing their widespread clinical application. To date, most MSC-based preclinical and clinical trials targeted immune-mediated and inflammatory diseases. Nevertheless, MSCs have antiviral properties and have been used in the treatment of various viral infections in the last years. Here, we revised in detail the biological properties of MSCs and their preclinical and clinical applications in viral diseases, including the disease caused by the severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2) infection (COVID-19). Notably, rapidly increasing numbers of MSC-based therapies for COVID-19 have recently been reported. MSCs are theoretically capable of reducing inflammation and promote lung regeneration in severe COVID-19 patients. We critically discuss the rationale, advantages and disadvantages of MSC-based therapies for viral infections and also specifically for COVID-19 and point out some directions in this field. Finally, we argue that MSC-based therapy may be a promising therapeutic strategy for severe COVID-19 and other emergent respiratory tract viral infections, beyond the viral infection diseases in which MSCs have already been clinically applied.

show abstract

“…The results confirmed the therapeutic potential of MSCs to treat patients with COVID-19 ( Fig. 4E and F) [105].…”

Section: Msc Therapy In Viral Infections: Preclinical and Clinical Apsupporting

confidence: 78%

Section: Msc Therapy In Viral Infections: Preclinical and Clinical Apmentioning

confidence: 99%

Section: Future Directions Of Msc-based Therapies For Covid-19 and Otmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19

Rocha

Oliveira

Noronha

et al. 2020

Stem Cell Rev and Rep

View full text Add to dashboard Cite

show abstract

“…It belongs to the β-coronavirus sub-family along with SARS-CoV and MERS-CoV [4,6]. The whole-genome sequence of SARS-CoV-2 consists of 29,903 nucleotides assigned with GenBank accession number MN908947 and the order of gene present was: replicase ORF1ab, spike (S), envelope (E), membrane (M) and nucleocapsid (N) in 5 0 to 3 0 direction of the viral genome [7,8,9]. WHO officially designated this new disease as coronavirus disease-2019, i.e., COVID-19.…”

Section: Introductionmentioning

confidence: 99%

“…These biomolecules have also been found to be effective during the previous epidemic due to SARS-CoV [17]. The phylogenetic analysis of SARS-CoV-2 with SARS-CoV has shown that they share 89.1% similarities among each other [7,8,9], the use of nucleic acid-based molecules against SARS-CoV-2 may emerge as a potential therapeutic strategy.…”

Section: Introductionmentioning

confidence: 99%

Nucleic acid-based therapy for coronavirus disease 2019

Piyush¹,

Rajarshi²,

Chatterjee³

et al. 2020

Heliyon

Self Cite

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19), the pandemic that originated in China has already spread into more than 190 countries, resulting in huge loss of human life and many more are at the stake of losing it; if not intervened with the best therapeutics to contain the disease. For that aspect, various scientific groups are continuously involved in the development of an effective line of treatment to control the novel coronavirus from spreading rapidly. Worldwide scientists are evaluating various biomolecules and synthetic inhibitors against COVID-19; where the nucleic acid-based molecules may be considered as potential drug candidates. These molecules have been proved potentially effective against SARS-CoV, which shares high sequence similarity with SARS-CoV-2. Recent advancements in nucleic acid-based therapeutics are helpful in targeted drug delivery, safely and effectively. The use of nucleic acid-based molecules also known to regulate the level of gene expression inside the target cells. This review mainly focuses on various nucleic acid-based biologically active molecules and their therapeutic potentials in developing vaccines for SARS-CoV-2.

show abstract

Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases

Banimohamad-Shotorbani

Farajpour

Sefat

et al. 2021

Biotech & Bioengineering

View full text Add to dashboard Cite

At the end of 2019, respiratory coronavirus diseases 2019 (COVID‐19) appeared and spread rapidly in the world. Besides several mutations, the outcome of this pandemic was the death up to 15% of hospitalized patients. Mesenchymal stromal cell therapy as a therapeutic strategy seemed successful in treatment of several diseases. Not only mesenchymal stromal cells of several tissues, but also their secreted extracellular vesicles and even secretome indicated beneficial therapeutic function. All of these three options were studied for treatment of COVID‐19 as well as those respiratory diseases that have similar symptom. Fortunately, most of the outcomes were promising and optimistic. In this paper, we review in‐vivo and clinical studies which have been used different sources of mesenchymal stromal cell, secreted extracellular vesicles, and secretome to improve and treat symptoms of COVID‐19 and similar lung diseases.

show abstract

Combating COVID-19 with mesenchymal stem cell therapy

Cited by 84 publications

References 22 publications

Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19

Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19

Nucleic acid-based therapy for coronavirus disease 2019

Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases

Contact Info

Product

Resources

About